TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12355937

Group type: EXPERIMENTAL
Intervention: Cisplatin plus irinotecan for advanced non-small cell lung cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin plus docetaxel for advanced non-small cell lung cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin plus irinotecan for small cell lung cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy for localized disease of both small and non-small cell lung cancers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant treatment methods for resected patients
Number of subjects: 0
Study: 9651406

Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8016028

Group type: EXPERIMENTAL
Intervention: Multiple risk factor intervention over 2 years
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Worksite as the unit of randomization and intervention
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Use of the transtheoretical stage of change model
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Volunteer resources within the worksite
Number of subjects: 25000
Study: 2687423

Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1097925

Group type: EXPERIMENTAL
Intervention: Propranolol (160 to 320 mg per day for six and 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31326727

Group type: EXPERIMENTAL
Intervention: liraglutide/metformin
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo/metformin
Number of subjects: 41
Study: 27878354

Group type: EXPERIMENTAL
Intervention: Cetuximab alone (Cet group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cetuximab and irinotecan (CetI group)
Number of subjects: 29
Study: 24927926

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study: 23155151

Group type: EXPERIMENTAL
Intervention: boceprevir (800 mg, 3 times daily) for 6 days followed by atazanavir (300 mg once daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: boceprevir (800 mg, 3 times daily) for 6 days followed by lopinavir (400 mg twice daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: boceprevir (800 mg, 3 times daily) for 6 days followed by darunavir (600 mg twice daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: boceprevir (800 mg, 3 times daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: ritonavir (100 mg)
Number of subjects: 39
Study: 21602430

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19672236

Group type: EXPERIMENTAL
Intervention: Acatinol (10 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Piracetam (1200 mg daily)
Number of subjects: 60
Study: 16968405

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS) fermented milk, 4 x 10(10) live LcS for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat-killed LcS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-IL-12 monoclonal antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Separation of NK cells from LcS-stimulated monocytes
Number of subjects: 0
Study: 16281467

Group type: EXPERIMENTAL
Intervention: Salk Polio Vaccine
Number of subjects: 1800000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1800000
Study: 11176469

Group type: EXPERIMENTAL
Intervention: Ureteroscopy via a 12-14Fr ureteral access sheath
Number of subjects: 59

Group type: COMPARATOR
Intervention: Unaided ureteroscopy with no access sheath
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ureteral access sheath used as a dilator
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Standard 18Fr ureteral balloon dilator
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Overall costs and operative time with access sheath
Number of subjects: 59
Study: 9250112

Group type: EXPERIMENTAL
Intervention: Iron-sufficient group (normal iron status)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iron-depleted group
Number of subjects: 30
Study: 8280654

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 40 mg daily
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 160 mg daily
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Combination of Tamoxifen and Megestrol acetate
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 184
Study: 2879457

Group type: EXPERIMENTAL
Intervention: Calcium entry blocker (nitrendipine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Beta adrenoreceptor blocker (oxprenolol)
Number of subjects: 40
Study: 31829907

Group type: EXPERIMENTAL
Intervention: Ganetespib 150 mg/m2 on days 1 and 15 with docetaxel 75 mg/m2 on day 1 of a 21-day cycle
Number of subjects: 677

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Ganetespib and docetaxel
Number of subjects: 677
Study: 29936130

Group type: EXPERIMENTAL
Intervention: Noninvasive image-guided breast brachytherapy (NIBB) with a total dose of 28.5 Gy in five daily fractions.
Number of subjects: 40
Study: 27904925

Group type: EXPERIMENTAL
Intervention: Sit Less
Number of subjects: 19

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sitting
Number of subjects: 19
Study: 24902881

Group type: EXPERIMENTAL
Intervention: Valsalva Manoeuvre (VM) in supine posture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Valsalva Manoeuvre (VM) in Trendelenberg posture
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Human Dive Reflex Manoeuvre (HDR) in supine posture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Human Dive Reflex Manoeuvre (HDR) in sitting posture
Number of subjects: 72
Study: 23139021

Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered cognitive behavioural therapy for 8 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Moderated online discussion forum (Control)
Number of subjects: 72
Study: 20477925

Group type: EXPERIMENTAL
Intervention: Acyclovir (400 mg five times a day for 1 week)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Follow-up
Number of subjects: 64
Study: 18565240

Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin beta (6000 IU weekly for 2 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Subcutaneous darbepoetin alfa (30 mug weekly for 2 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Patient preference for treatment
Number of subjects: 48
Study: 16648085

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment based on acupuncture diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blinding in RCTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham techniques
Number of subjects: 0
Study: 12771834

Group type: EXPERIMENTAL
Intervention: Clinic-based rehabilitation provided by outpatient physical therapists
Number of subjects: 160

Group type: COMPARATOR
Intervention: Home-based rehabilitation monitored by periodic telephone calls from a physical therapist
Number of subjects: 160
Study: 10837296

Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin diet
Number of subjects: 29

Group type: COMPARATOR
Intervention: sodium-caseinate diet
Number of subjects: 29
Study: 9176531

Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase, 250,000 i.u. daily for three days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control saline flushes for three days
Number of subjects: 24
Study: 1545974

Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine intra‐alveolar dressings
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline solution intra‐alveolar dressings
Number of subjects: 70
Study: 2865718

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 0
Study: 30340935

Group type: EXPERIMENTAL
Intervention: Older age (≥12 months)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Commercial insurance
Number of subjects: 660

Group type: COMPARATOR
Intervention: Race, ethnicity, primary caregiver's education level, and income
Number of subjects: 660
Study: 30517038

Group type: EXPERIMENTAL
Intervention: Staging at 2500m for 2 days
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Staging at 3000m for 2 days
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Staging at 3500m for 2 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Direct ascent to 4300m (Control)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Staging at 2500m
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Staging at 3000m
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Staging at 3500m
Number of subjects: 65
Study: 26406287

Group type: EXPERIMENTAL
Intervention: PRT + TME (5 × 5 Gy)
Number of subjects: 1530

Group type: COMPARATOR
Intervention: TME alone
Number of subjects: 1530
Study: 24468539

Group type: EXPERIMENTAL
Intervention: Old age
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low triglyceride
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Periventricular WMC (PVWMC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Presence of thalamic microbleed
Number of subjects: 100
Study: 23176989

Group type: EXPERIMENTAL
Intervention: Bupivacaine soaked in Gelfoam(®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 20231185

Group type: EXPERIMENTAL
Intervention: Public disclosure process via brochure and poster in PICU waiting rooms
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Brochure
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Poster
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Public disclosure process
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Opt-out option awareness
Number of subjects: 93
Study: 17384010

Group type: EXPERIMENTAL
Intervention: Intensively treated patients after stabilization of glycemia (from 6 months onward)
Number of subjects: 11727

Group type: EXPERIMENTAL
Intervention: Intensively treated patients at baseline
Number of subjects: 11727

Group type: COMPARATOR
Intervention: Conventionally treated patients from 6 months onward
Number of subjects: 11727
Study: 16353046

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg) with hydrochlorothiazide (25 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Captopril (50 mg) with hydrochlorothiazide (25 mg)
Number of subjects: 60
Study: 16923694

Group type: EXPERIMENTAL
Intervention: Cod liver oil (n-3 PUFAs)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Corn oil (n-6 PUFAs)
Number of subjects: 590
Study: 10924001

Group type: EXPERIMENTAL
Intervention: d,l‐fenfluramine (100 mg orally)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 8638784

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 214

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 214
Study: 1387512

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 40 micrograms via Ingelheim powder device (IPI)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 40 micrograms via metered dose inhaler (MDI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ipratropium bromide (IB) 40 micrograms
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fenoterol (not specified dosage)
Number of subjects: 70
Study: 6516414

Group type: EXPERIMENTAL
Intervention: Theophylline administered in aqueous solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theophylline oral preparations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration of Theophylline
Number of subjects: 0
Study: 31187518

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 394
Study: 30397015

Group type: EXPERIMENTAL
Intervention: AURAS‐AF software tool for risk assessment and reminders during consultations
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with clinicians and patients
Number of subjects: 476
Study: 27137756

Group type: EXPERIMENTAL
Intervention: sufentanil 2.5 μg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: sufentanil 5 μg
Number of subjects: 180

Group type: COMPARATOR
Intervention: fentanyl 25 μg
Number of subjects: 180
Study: 24835719

Group type: EXPERIMENTAL
Intervention: Formulary applications for new drugs or new indications (95 applications)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Applications reviewed by statewide medicines advisory committee or hospital pharmacist (45 applications)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Applications including randomised controlled trials (37 applications)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Applications including case series (36 applications)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Applications including product information (34 applications)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Applications including narrative reviews (29 applications)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Applications including systematic review or meta-analysis (14 applications)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Applications with a declared conflict of interest (10 applications)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Evaluation of risk of bias of supporting studies
Number of subjects: 120
Study: 22540419

Group type: EXPERIMENTAL
Intervention: School-based toothbrushing programme (SBTB) for 2 years
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (non-SBTB)
Number of subjects: 150
Study: 20298560

Group type: EXPERIMENTAL
Intervention: Personalised physical activity feedback ('simple')
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Personalised physical activity feedback ('visualised')
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Personalised physical activity feedback ('contextualised')
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 500
Study: 18049317

Group type: EXPERIMENTAL
Intervention: Parental report using the Diagnostic Interview Schedule for Children (DISC)
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: ADHD medication use
Number of subjects: 1070
Study: 16259507

Group type: EXPERIMENTAL
Intervention: Nicotine gum and motivational interviewing
Number of subjects: 813

Group type: COMPARATOR
Intervention: Health fairs for recruitment
Number of subjects: 813
Study: 11834115

Group type: EXPERIMENTAL
Intervention: Creatine (0.3 g x kg(‐1) x d(‐1)) with 1-minute recovery interval
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Creatine (0.3 g x kg(‐1) x d(‐1)) with 3-minute recovery interval
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Placebo with 6-minute recovery interval
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Placebo with 1-minute recovery interval
Number of subjects: 30
Study: 11798639

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Number of subjects: 75

Group type: COMPARATOR
Intervention: All-trans retinoic acid
Number of subjects: 75
Study: 7743615

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (rTPA)
Number of subjects: 2634

Group type: COMPARATOR
Intervention: Invasive post-lytic management strategy
Number of subjects: 2634

Group type: EXPERIMENTAL
Intervention: Non-Q-wave infarct
Number of subjects: 2634
Study: 30605708

Group type: EXPERIMENTAL
Intervention: Add-on 10Hz rTMS treatment (20 times)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine addiction rehabilitation
Number of subjects: 90
Study: 28864955

Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal (TEP) repair
Number of subjects: 98

Group type: COMPARATOR
Intervention: Open inguinal hernia (Shouldice) repair
Number of subjects: 98
Study: 25886569

Group type: EXPERIMENTAL
Intervention: Enhanced motivational interviewing (MI) intervention delivered in group or individual formats, 10 sessions plus an introductory session over one year.
Number of subjects: 1704

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: Enhanced MI intervention
Number of subjects: 1704
Study: 23759326

Group type: EXPERIMENTAL
Intervention: Screening every 4 years with PSA level cut-off ≥ 3.0 ng/ml as biopsy indication (S-arm)
Number of subjects: 42376

Group type: COMPARATOR
Intervention: No intervention (C-arm)
Number of subjects: 42376
Study: 21342773

Group type: EXPERIMENTAL
Intervention: Adenosine pretreatment (2.45 mg kg⁻¹ over 10 min)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Adenosine pretreatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 82
Study: 18539916

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (gliclazide modified release plus other drugs)
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study: 16019923

Group type: COMPARATOR
Intervention: Control
Number of subjects: 385
Study: 12768462

Group type: EXPERIMENTAL
Intervention: Acamprosate (1332 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 10228313

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 125
Study: 8898507

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 25 micrograms/hr
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 50 micrograms/hr
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 35
Study: 1725280

Group type: EXPERIMENTAL
Intervention: PPF (DDP 100 mg/m2 + pingyangmycin + 5‐FU) regimen plus radiotherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 64
Study: 6654768

Group type: EXPERIMENTAL
Intervention: Training and consultation package designed to increase the reinforcing ambience of the school
Number of subjects: 18
Study: 30678662

Group type: EXPERIMENTAL
Intervention: Assessment of student performance using the APP tool at 'not adequate' level
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Assessment of student performance using the APP tool at 'good/excellent' level
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Assessment of student performance using the APP tool at 'adequate' level
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Differentiating 'not adequate' from 'adequate' or better
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Assessment across clinical areas for 'not adequate' and 'good/excellent' levels
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Assessment across clinical areas for 'adequate' level
Number of subjects: 153
Study: 29693483

Group type: EXPERIMENTAL
Intervention: Cognitive training (n=44)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Aerobic training (n=47)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No additional training (n=41)
Number of subjects: 132
Study: 27854209

Group type: EXPERIMENTAL
Intervention: Aceneuramic acid extended-release (Ace-ER) 6g/day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined 6g/day group after crossover
Number of subjects: 47

Group type: COMPARATOR
Intervention: Aceneuramic acid extended-release (Ace-ER)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined 6g/day group
Number of subjects: 47
Study: 24559216

Group type: EXPERIMENTAL
Intervention: Intensive combination treatment strategies (ICTS) for early RA
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional disease-modifying anti-rheumatic drugs (DMARDs) plus step-down glucocorticoids (GCs)
Number of subjects: 32
Study: 22759883

Group type: EXPERIMENTAL
Intervention: Home-based resistance training (RT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group receiving standard care
Number of subjects: 41
Study: 20639252

Group type: EXPERIMENTAL
Intervention: Biennial faecal occult blood testing (FOBT) screening
Number of subjects: 78708

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 78708

Group type: EXPERIMENTAL
Intervention: Participants receiving negative test results
Number of subjects: 78708

Group type: EXPERIMENTAL
Intervention: Participants in screening
Number of subjects: 78708

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 78708

Group type: EXPERIMENTAL
Intervention: Participants receiving positive test results
Number of subjects: 78708
Study: 18692637

Group type: EXPERIMENTAL
Intervention: Esmolol (125 microg/kg)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Esmolol (250 microg/kg)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Esmolol (500 microg/kg)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Esmolol (all doses)
Number of subjects: 116
Study: 15778268

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.04 mg kg(‐1) and glycopyrrolate 0.01 mg kg(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glycopyrrolate alone
Number of subjects: 40
Study: 12501883

Group type: EXPERIMENTAL
Intervention: Oral gemifloxacin 320 mg once daily (7-14 days)
Number of subjects: 345

Group type: COMPARATOR
Intervention: IV ceftriaxone 2 g once daily (1-7 days) followed by oral cefuroxime 500 mg twice daily (1-13 days)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 345